NextCure (NXTC) Competitors $6.65 +0.12 (+1.84%) Closing price 04:00 PM EasternExtended Trading$6.50 -0.15 (-2.27%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock NXTC vs. ALGS, GNTA, ACRV, IMMX, DRRX, ELYM, BRNS, ICCC, CELU, and CUEShould you be buying NextCure stock or one of its competitors? The main competitors of NextCure include Aligos Therapeutics (ALGS), Genenta Science (GNTA), Acrivon Therapeutics (ACRV), Immix Biopharma (IMMX), DURECT (DRRX), Eliem Therapeutics (ELYM), Barinthus Biotherapeutics (BRNS), ImmuCell (ICCC), Celularity (CELU), and Cue Biopharma (CUE). These companies are all part of the "pharmaceutical products" industry. NextCure vs. Its Competitors Aligos Therapeutics Genenta Science Acrivon Therapeutics Immix Biopharma DURECT Eliem Therapeutics Barinthus Biotherapeutics ImmuCell Celularity Cue Biopharma NextCure (NASDAQ:NXTC) and Aligos Therapeutics (NASDAQ:ALGS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, profitability, institutional ownership, media sentiment, valuation, earnings and analyst recommendations. Which has more risk & volatility, NXTC or ALGS? NextCure has a beta of 1.34, meaning that its share price is 34% more volatile than the S&P 500. Comparatively, Aligos Therapeutics has a beta of 2.77, meaning that its share price is 177% more volatile than the S&P 500. Do insiders & institutionals believe in NXTC or ALGS? 42.7% of NextCure shares are owned by institutional investors. Comparatively, 60.4% of Aligos Therapeutics shares are owned by institutional investors. 17.9% of NextCure shares are owned by company insiders. Comparatively, 4.8% of Aligos Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has better earnings & valuation, NXTC or ALGS? NextCure has higher earnings, but lower revenue than Aligos Therapeutics. Aligos Therapeutics is trading at a lower price-to-earnings ratio than NextCure, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNextCureN/AN/A-$55.65M-$25.82-0.26Aligos Therapeutics$3.94M14.72-$131.21M-$19.79-0.48 Is NXTC or ALGS more profitable? NextCure has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -2,337.24%. Aligos Therapeutics' return on equity of -22.41% beat NextCure's return on equity.Company Net Margins Return on Equity Return on Assets NextCureN/A -106.62% -85.20% Aligos Therapeutics -2,337.24%-22.41%-12.09% Do analysts recommend NXTC or ALGS? NextCure presently has a consensus price target of $25.50, indicating a potential upside of 283.46%. Aligos Therapeutics has a consensus price target of $50.00, indicating a potential upside of 430.22%. Given Aligos Therapeutics' higher possible upside, analysts plainly believe Aligos Therapeutics is more favorable than NextCure.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NextCure 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25Aligos Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the media refer more to NXTC or ALGS? In the previous week, Aligos Therapeutics had 3 more articles in the media than NextCure. MarketBeat recorded 6 mentions for Aligos Therapeutics and 3 mentions for NextCure. NextCure's average media sentiment score of 0.88 beat Aligos Therapeutics' score of 0.84 indicating that NextCure is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NextCure 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aligos Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryAligos Therapeutics beats NextCure on 8 of the 15 factors compared between the two stocks. Get NextCure News Delivered to You Automatically Sign up to receive the latest news and ratings for NXTC and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NXTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NXTC vs. The Competition Export to ExcelMetricNextCureMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$17.48M$3.38B$6.11B$10.63BDividend YieldN/A2.29%5.66%4.71%P/E Ratio-0.2621.9785.2726.57Price / SalesN/A462.21612.79132.68Price / CashN/A47.2238.5062.09Price / Book0.2410.2112.726.53Net Income-$55.65M-$52.40M$3.30B$275.96M7 Day Performance15.95%0.88%1.05%-1.40%1 Month Performance21.13%12.35%7.56%5.16%1 Year Performance-59.84%30.13%79.69%31.55% NextCure Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NXTCNextCure4.5232 of 5 stars$6.65+1.8%$25.50+283.5%-57.2%$17.48MN/A-0.2690Analyst ForecastGap DownHigh Trading VolumeALGSAligos Therapeutics3.8585 of 5 stars$10.22+1.5%$50.00+389.2%+31.6%$62.87M$3.17M-0.5290Analyst ForecastGNTAGenenta Science0.9253 of 5 stars$3.22-2.4%N/A-41.2%$60.36MN/A0.007News CoveragePositive NewsAnalyst ForecastACRVAcrivon Therapeutics2.7187 of 5 stars$1.91flat$15.00+685.3%-72.0%$60.08MN/A-0.8558Positive NewsAnalyst ForecastIMMXImmix Biopharma3.1671 of 5 stars$2.24+8.7%$8.00+257.1%+67.5%$59.40MN/A-2.919Analyst ForecastGap UpHigh Trading VolumeDRRXDURECT0.9201 of 5 stars$1.91flatN/AN/A$59.31M$1.66M-19.1080ELYMEliem TherapeuticsN/A$1.98-2.9%N/A-65.6%$58.91MN/A-3.749High Trading VolumeBRNSBarinthus Biotherapeutics2.4612 of 5 stars$1.57+8.6%$3.00+91.1%+22.7%$58.85M$14.97M-0.91107Gap UpICCCImmuCell1.1048 of 5 stars$6.35+0.6%N/A+84.1%$57.08M$26.49M33.4270News CoveragePositive NewsAnalyst ForecastGap DownCELUCelularity2.0559 of 5 stars$2.08-2.3%$6.00+188.5%-12.7%$56.85M$54.22M-0.65220News CoverageAnalyst ForecastCUECue Biopharma2.3826 of 5 stars$0.73-0.2%N/A-23.1%$56.03M$8.29M-1.3060News CoveragePositive NewsShort Interest ↓ Related Companies and Tools Related Companies ALGS Competitors GNTA Competitors ACRV Competitors IMMX Competitors DRRX Competitors ELYM Competitors BRNS Competitors ICCC Competitors CELU Competitors CUE Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NXTC) was last updated on 10/10/2025 by MarketBeat.com Staff From Our PartnersBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredURGENT: The Market's 3 Red Flags Are FlashingThe warning signs that preceded the 2008 crash are reappearing: an irrational NASDAQ bubble, a record-high gol...StockEarnings | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | SponsoredRobinhood warningA strange chasm is coming to Wall Street... It's already creating millionaires and billionaires at the fast...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NextCure, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NextCure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
